Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue: +11.9%
EPS: −39.2%
Free cash flow: −52.1%

Quarter to September 2026, against a year earlier

547.08 4.58 +0.84%

Follow VRTX

Alert me

Market cap: $137.5B
P/E: 34.6×
Fwd P/E: 33.2×
Dividend yield: —
F-score: 8/9
Altman Z: 12.06
Beneish M: −2.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Vertex Pharmaceuticals Incorporated (VRTX) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 34.6×. Over the past ten years it has ranged from 0.0× (June 2025) to 194× (October 2017); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VRTX/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Vertex Pharmaceuticals Incorporated P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VRTX/metrics/pe-ratio">Vertex Pharmaceuticals Incorporated (VRTX) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	29.3×	—
FY2024	0.0×	—
FY2023	29.3×	32.82%
FY2022	22.0×	(8.69%)
FY2021	24.1×	6.40%
FY2020	22.7×	(52.66%)
FY2019	47.9×	138.24%
FY2018	20.1×	(85.93%)
FY2017	143×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Sep 2026	33.4×	16.41%
Jun 2026	28.7×	9.19%
Mar 2026	26.3×	(10.42%)
Dec 2025	29.3×	7.23%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 194×

Ten-year median 25.0×

Current reading's percentile 73

Company	P/E ratio
ROIV Roivant Sciences Ltd. compare	n/m
MRNA Moderna, Inc. compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
REGN Regeneron Pharmaceuticals, Inc. compare	19.2×
ARGX argenex SE compare	29.8×
VRTX Vertex Pharmaceuticals Incorporated	34.6×
GMAB Genmab A/S Sponsored ADR compare	41.7×
RPRX Royalty Pharma PLC compare	44.8×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	65.9×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Vertex Pharmaceuticals Incorporated (VRTX) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on VRTX

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on VRTX

Stockrow Weekly